Rare Disease Products Mostly Approved With Regulatory Flexibility, NORD "Catalog" Finds

NORD makes the case that FDA should codify unconventional approaches by arguing that the agency already uses them for two-thirds of its orphan approvals.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet